Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
INSM

Prezzo Insmed Incorporated

INSM
$134,00
+$0,03(+0,02%)

*Data last updated: 2026-05-04 10:42 (UTC+8)

As of 2026-05-04 10:42, Insmed Incorporated (INSM) is priced at $134,00, with a total market cap of $28,76B, a P/E ratio of -29,12, and a dividend yield of 0,00%. Today, the stock price fluctuated between $134,00 and $134,00. The current price is 0,00% above the day's low and 0,00% below the day's high, with a trading volume of 1,56M. Over the past 52 weeks, INSM has traded between $132,39 to $166,88, and the current price is -19,70% away from the 52-week high.

INSM Key Stats

Yesterday's Close$136,33
Market Cap$28,76B
Volume1,56M
P/E Ratio-29,12
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)5,98
Net Income (FY)-$1,27B
Revenue (FY)$606,42M
Earnings Date2026-05-07
EPS Estimate0,97
Revenue Estimate$299,05M
Shares Outstanding210,99M
Beta (1Y)1.101

About INSM

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
SectorHealthcare
IndustryBiotechnology
CEOWilliam H. Lewis
HeadquartersBridgewater,NJ,US
Official Websitehttps://www.insmed.com
Employees (FY)1,66K
Average Revenue (1Y)$364,43K
Net Income per Employee-$767,29K

Insmed Incorporated (INSM) FAQ

What's the stock price of Insmed Incorporated (INSM) today?

x
Insmed Incorporated (INSM) is currently trading at $134,00, with a 24h change of +0,02%. The 52-week trading range is $132,39–$166,88.

What are the 52-week high and low prices for Insmed Incorporated (INSM)?

x

What is the price-to-earnings (P/E) ratio of Insmed Incorporated (INSM)? What does it indicate?

x

What is the market cap of Insmed Incorporated (INSM)?

x

What is the most recent quarterly earnings per share (EPS) for Insmed Incorporated (INSM)?

x

Should you buy or sell Insmed Incorporated (INSM) now?

x

What factors can affect the stock price of Insmed Incorporated (INSM)?

x

How to buy Insmed Incorporated (INSM) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

INSM
CFD
Fai trading

Hot Posts su Insmed Incorporated (INSM)

SelfRugger

SelfRugger

05-01 05:32
How Recent Analyst Shifts And Brinsupri Milestones Are Reframing The Insmed (INSM) Story ======================================================================================== Simply Wall St Thu, February 19, 2026 at 12:14 PM GMT+9 5 min read In this article: INSM +0.39% Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest update to our Insmed narrative shows only a slight reset in the numbers, with the blended fair value estimate edging from about US$215.10 to roughly US$214.37 per share as assumptions around long term revenue growth and the discount rate are nudged closer to where recent Street research is clustering. Behind that small move is a tug of war between bullish analysts, who point to Brinsupri progress and growing institutional interest, and more cautious voices who highlight funding needs, commercialization risk, and sector wide sentiment. Stay with this article to see how you can keep track of these shifting inputs and the evolving story around Insmed from here. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Insmed. What Wall Street Has Been Saying -------------------------------- Recent Street research on Insmed continues to skew constructive, with several firms updating their views and targets in January 2026. Together, these notes feed directly into how analysts are thinking about the risk reward trade off around valuation, execution, and growth potential. **🐂 Bullish Takeaways** * Roth Capital and Barclays both initiated coverage with bullish views in January, adding to the group of firms that see sufficient growth potential and execution progress to support constructive stances on the stock. * UBS keeps a Buy rating while adjusting its price target to US$215 from US$223, tying its view to a cautiously optimistic setup for biotech, with potential support from a large pool of pending M&A capital that could help sentiment toward commercial stage names such as Insmed. * Morgan Stanley maintains an Equal Weight rating with a US$157 target and highlights U.S. small to mid cap biotech as a group where commercial companies are seen transitioning from capital consumers to capital producers, which frames how investors might think about Insmed's path to funding its pipeline and commercial efforts. **🐻 Bearish Takeaways** * Even among supportive firms, target moves at UBS and Morgan Stanley are slightly lower, which signals some caution around how much upside is already reflected in current expectations and the sector's capital needs. * Morgan Stanley's Equal Weight stance and US$157 target sit below more bullish numbers like the UBS US$215 target. This underscores that some analysts are more guarded on valuation, near term funding dynamics, and execution risk around turning commercial progress into durable cash generation. Story Continues Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives! NasdaqGS:INSM 1-Year Stock Price Chart What's in the News ------------------ * Insmed issued full year 2025 revenue guidance, with the company expecting total revenues of US$606.4 million compared with US$363.7 million reported a year earlier, giving investors a clearer sense of management's current outlook for the business. * The stock was added to the NASDAQ-100 Index, bringing Insmed into one of the most widely followed large cap benchmarks on the exchange, which can put the name in front of more index and benchmark aware investors. * The Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps did not meet its primary or secondary efficacy endpoints. Insmed has discontinued development of brensocatib for this indication, while reporting that the drug was well tolerated in the trial with no new safety signals identified, including at the 40 mg dose. * Following the BiRCh outcome, Insmed plans to advance Phase 2 programs for INS1148 in interstitial lung disease and in moderate to severe asthma. This keeps attention on the wider pipeline beyond brensocatib in this specific setting. How This Changes the Fair Value For Insmed ------------------------------------------ * Fair Value: the blended fair value estimate edges down slightly from about US$215.10 to roughly US$214.37 per share, reflecting small tweaks to the underlying assumptions rather than a wholesale shift in the thesis. * Discount Rate: the discount rate assumption trims down a bit from about 7.13% to roughly 7.06%, which modestly increases the present value placed on future cash flows in the model. * Revenue Growth: the long term revenue growth input is adjusted slightly lower from about 97.00% to roughly 96.82%, signaling a very small recalibration of how quickly the top line is expected to scale in the later forecast years. * Net Profit Margin: the modeled net profit margin ticks up from about 23.79% to roughly 23.85%, a small adjustment that assumes slightly greater efficiency in translating revenues into earnings over time. * Future P/E: the future P/E multiple assumption eases slightly from about 84.91x to roughly 84.46x, suggesting a marginally more restrained view on how much investors might be willing to pay for those modeled earnings. 🔔 Never Miss an Update: Follow The Narrative --------------------------------------------- Narratives on Simply Wall St let you connect Insmed's story with the numbers by linking a clear viewpoint on the company to forecasts for revenue, earnings and margins, and then to a fair value. They sit inside the Community page, are easy to read, and help you compare fair value to the current share price. As news, clinical data, or earnings arrive, the narrative updates so you can quickly reassess your view without rebuilding your model from scratch. Head over to the Simply Wall St Community and follow the Insmed narrative to stay on top of what matters most for this story: INSM: European Respiratory Approval And NASDAQ Inclusion Will Support Future Platform Expansion. You will be kept up to date on: * How anticipated U.S. and international brensocatib launches, along with ARIKAYCE label expansion, are built into revenue and earnings forecasts. * What assumptions sit behind the long term profit margin, discount rate and high future P/E multiple used to reach the current fair value for Insmed. * Which clinical, regulatory and payer related risks could challenge the revenue path that underpins the analyst price target range. Curious how numbers become stories that shape markets? Explore Community Narratives _ This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ _Companies discussed in this article include INSM._ **Have feedback on this article? Concerned about the content? Get in touch with us directly.**_ Alternatively, email [email protected]_ Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0
BlockchainArchaeologist

BlockchainArchaeologist

2025-12-26 01:44
Insmed Inc. (INSM) faced a significant market disappointment after disclosing that its Phase 2b BiRCh trial for brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) failed to achieve both primary and secondary efficacy endpoints across the 10 mg and 40 mg dosing cohorts. The clinical setback prompted the company to immediately halt all development efforts for brensocatib in this indication. ## Market Reaction and Stock Performance Investor sentiment turned decidedly negative following the announcement, with INSM shares plummeting 21.39% in after-hours trading. The stock closure on Wednesday had already reflected some bearish pressure, finishing at $198.46, down 1.10% on the day. Over the trailing twelve-month period, INSM has oscillated between a low of $60.40 and a high of $212.75, painting a picture of volatility in the biopharmaceutical sector. ## Strategic Pivot: INS1148 Acquisition To offset the clinical failure, Insmed announced a strategic acquisition of INS1148 (previously designated OpSCF), a Phase 2-ready monoclonal antibody candidate originally developed by Opsidio, a private clinical-stage biotech firm. While acquisition terms remained undisclosed, the deal signals management's commitment to redirecting resources toward alternative therapeutic pathways. The company intends to advance INS1148 into Phase 2 development targeting two indications: interstitial lung disease and moderate-to-severe asthma—both representing significant unmet medical needs. ## Company Commentary Dr. Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed, acknowledged the disappointment while framing the outcome constructively: "While we are disappointed in the results, they provided us with a clear answer. We extend our sincerest gratitude to the patients and investigators who made the BiRCh study possible." The acquisition represents management's pragmatic approach to portfolio optimization, leveraging the acquired monoclonal antibody platform to pursue potentially more tractable respiratory and inflammatory targets.
0
0
0
0
PuzzledScholar

PuzzledScholar

01-04 15:11
**The Catalyst Behind INSM's Remarkable Rise** Insmed, Inc. (INSM) has witnessed an impressive 78% climb in stock value over the past six months, marking a significant outperformance compared to broader market trends. This robust rally has been primarily fueled by two major developments: FDA regulatory approval for a breakthrough therapy and exceptional commercial performance from its existing product portfolio. The company's most significant achievement came in August 2025 with FDA clearance of brensocatib, marketed as Brinsupri, establishing it as the first approved treatment for non-cystic fibrosis bronchiectasis (NCFB). This approval was subsequently followed by European Union authorization in November 2025, positioning Insmed to access a multi-billion-dollar treatment opportunity. Beyond the regulatory milestone, Brinsupri demonstrated impressive market acceptance, generating $28.1 million in third-quarter revenues despite launching only months earlier—a testament to strong physician and patient demand. **Revenue Performance and Market Expansion** The company's established product, Arikayce, continues to serve as a reliable revenue generator, with $314.5 million in sales through the first nine months of 2025, representing 21% year-over-year growth. This steady commercial momentum prompted management to raise 2025 guidance, now projecting global Arikayce revenues between $420 million and $430 million, up from the previous guidance range of $405 million to $425 million. Over the trailing twelve-month period, INSM shares have appreciated 149.2%, meaningfully outpacing the broader industry benchmark of 17.5% growth. The strength in existing product sales has helped mitigate near-term financial pressures, providing runway for continued pipeline development. **Pipeline Progress and Recent Setbacks** While Brinsupri's approval represents a watershed moment for Insmed, recent developments have been mixed. The company encountered a significant setback when its phase IIb BiRCh trial evaluating brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) failed to achieve primary efficacy endpoints, leading to discontinuation of this development program. However, Insmed has offset this disappointment through strategic pipeline additions. In December, the company acquired INS1148, a monoclonal antibody targeting interstitial lung disease and moderate-to-severe asthma, which will advance through mid-stage clinical studies. Additionally, the company is progressing several other late-stage programs, including the phase II CEDAR study assessing brensocatib in hidradenitis suppurativa (HS), with results anticipated in the first half of 2026, and the phase III ENCORE trial examining Arikayce in newly diagnosed MAC lung disease patients, with data expected in early 2026. **Investment Outlook and Comparative Positioning** Insmed carries a Zacks Rank #3 (Hold) rating, reflecting a measured outlook amid both achievements and challenges. The company's ability to generate meaningful revenues from Brinsupri while advancing a diversified pipeline positions it well for sustained growth, though investors should monitor pipeline progression closely as clinical development outcomes will meaningfully influence future performance trajectories.
0
0
0
0